About The Study: The findings of this study show that, after the end of the semaglutide and tirzepatide shortages, compounding facilities have continued to manufacture glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with added ingredients. Compounded GLP-1 RA sourcing is diverse but includes facilities without licenses to perform sterile compounding or that have been subject to recent disciplinary action, posing clinical and regulatory challenges.
Corresponding Author: To contact the corresponding author, Michael J. DiStefano, PhD, email michael.j.distefano@cuanschutz.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2026.2207)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.2207?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071726
JAMA Health Forum